TY - JOUR
T1 - The causal effect of tracing by peer health workers on return to clinic among patients who were lost to follow-up from antiretroviral therapy in Eastern Africa
T2 - A “natural experiment” arising from surveillance of lost patients
AU - East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium
AU - Bershetyn, Anna
AU - Odeny, Thomas A.
AU - Lyamuya, Rita
AU - Nakiwogga-Muwanga, Alice
AU - Diero, Lameck
AU - Bwana, Mwebesa
AU - Braitstein, Paula
AU - Somi, Geoffrey
AU - Kambugu, Andrew
AU - Bukusi, Elizabeth
AU - Hartogensis, Wendy
AU - Glidden, David V.
AU - Wools-Kaloustian, Kara
AU - Yiannoutsos, Constantin
AU - Martin, Jeffrey
AU - Geng, Elvin H.
N1 - Publisher Copyright:
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Background. The effect of tracing human immunodeficiency virus (HIV)–infected patients who are lost to follow-up (LTFU) on reengagement has not been rigorously assessed. We carried out an ex post analysis of a surveillance study in which LTFU patients were randomly selected for tracing to identify the effect of tracing on reengagement. Methods. We evaluated HIV-infected adults on antiretroviral therapy who were LTFU (>90 days late for last visit) at 14 clinics in Uganda, Kenya, and Tanzania. A random sample of LTFU patients was selected for tracing by peer health workers. We assessed the effect of selection for tracing using Kaplan-Meier estimates of reengagement among all patients as well as the subset of LTFU patients who were alive, contacted in person by the tracer, and out of care. Results. Of 5781 eligible patients, 991 (17%) were randomly selected for tracing. One year after selection for tracing, 13.3% (95% confidence interval [CI], 11.1%–15.3%) of those selected for tracing returned compared with 10.0% (95% CI, 9.1%–10.8%) of those not randomly selected, an adjusted risk difference of 3.0% (95% CI, .7%–5.3%). Among patients found to be alive, personally contacted, and out of care, tracing increased the absolute probability of return at 1 year by 22% (95% CI, 7.1%–36.2%). The effect of tracing on rate of return to clinic decayed with a half-life of 7.0 days after tracing (95% CI, 2.6 %–12.9%). Conclusions. Tracing interventions increase reengagement, but developing methods for targeting LTFU patients most likely to benefit can make this practice more efficient.
AB - Background. The effect of tracing human immunodeficiency virus (HIV)–infected patients who are lost to follow-up (LTFU) on reengagement has not been rigorously assessed. We carried out an ex post analysis of a surveillance study in which LTFU patients were randomly selected for tracing to identify the effect of tracing on reengagement. Methods. We evaluated HIV-infected adults on antiretroviral therapy who were LTFU (>90 days late for last visit) at 14 clinics in Uganda, Kenya, and Tanzania. A random sample of LTFU patients was selected for tracing by peer health workers. We assessed the effect of selection for tracing using Kaplan-Meier estimates of reengagement among all patients as well as the subset of LTFU patients who were alive, contacted in person by the tracer, and out of care. Results. Of 5781 eligible patients, 991 (17%) were randomly selected for tracing. One year after selection for tracing, 13.3% (95% confidence interval [CI], 11.1%–15.3%) of those selected for tracing returned compared with 10.0% (95% CI, 9.1%–10.8%) of those not randomly selected, an adjusted risk difference of 3.0% (95% CI, .7%–5.3%). Among patients found to be alive, personally contacted, and out of care, tracing increased the absolute probability of return at 1 year by 22% (95% CI, 7.1%–36.2%). The effect of tracing on rate of return to clinic decayed with a half-life of 7.0 days after tracing (95% CI, 2.6 %–12.9%). Conclusions. Tracing interventions increase reengagement, but developing methods for targeting LTFU patients most likely to benefit can make this practice more efficient.
KW - Africa
KW - Antiretroviral therapy
KW - Loss to follow-up
KW - Retention
UR - http://www.scopus.com/inward/record.url?scp=85027301826&partnerID=8YFLogxK
U2 - 10.1093/cid/cix191
DO - 10.1093/cid/cix191
M3 - Article
C2 - 28329184
AN - SCOPUS:85027301826
SN - 1058-4838
VL - 64
SP - 1547
EP - 1554
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 11
ER -